Clinical Trial Update: Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating liposomal irinotecan in combination with sintilimab and anlotinib for recurrent or persistent ovarian clear c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Clear Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Onivyde (irinotecan hydrochloride liposome injection)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Ovarian Cancer, Ovarian Clear Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING